JP2017524715A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524715A5
JP2017524715A5 JP2017507739A JP2017507739A JP2017524715A5 JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5 JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding portion
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507739A
Other languages
English (en)
Japanese (ja)
Other versions
JP6654187B2 (ja
JP2017524715A (ja
Filing date
Publication date
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/068598 external-priority patent/WO2016023960A1/en
Publication of JP2017524715A publication Critical patent/JP2017524715A/ja
Publication of JP2017524715A5 publication Critical patent/JP2017524715A5/ja
Application granted granted Critical
Publication of JP6654187B2 publication Critical patent/JP6654187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507739A 2014-08-12 2015-08-12 抗ｃｄ４０抗体を用いた併用療法 Active JP6654187B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1414270.7 2014-08-12
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB1422614.6 2014-12-18
GB201422614 2014-12-18
GB1507541.9 2015-05-01
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (3)

Publication Number Publication Date
JP2017524715A JP2017524715A (ja) 2017-08-31
JP2017524715A5 true JP2017524715A5 (Direct) 2018-09-27
JP6654187B2 JP6654187B2 (ja) 2020-02-26

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507739A Active JP6654187B2 (ja) 2014-08-12 2015-08-12 抗ｃｄ４０抗体を用いた併用療法

Country Status (25)

Country Link
US (3) US11149090B2 (Direct)
EP (3) EP4653463A2 (Direct)
JP (1) JP6654187B2 (Direct)
KR (1) KR102443258B1 (Direct)
CN (3) CN119280407A (Direct)
AU (1) AU2015303164B2 (Direct)
CA (1) CA2957146A1 (Direct)
CL (1) CL2017000335A1 (Direct)
CO (1) CO2017001317A2 (Direct)
CR (1) CR20170096A (Direct)
DK (1) DK3180087T3 (Direct)
EA (1) EA201790339A1 (Direct)
EC (1) ECSP17008984A (Direct)
ES (1) ES2725463T3 (Direct)
IL (1) IL250512B (Direct)
MA (1) MA47472A (Direct)
MX (1) MX382549B (Direct)
NI (1) NI201700015A (Direct)
PE (1) PE20170680A1 (Direct)
PH (1) PH12017500229A1 (Direct)
SG (1) SG11201701070WA (Direct)
SV (1) SV2017005380A (Direct)
UA (1) UA119783C2 (Direct)
WO (1) WO2016023960A1 (Direct)
ZA (1) ZA201701126B (Direct)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
EP4292664A3 (en) 2015-05-15 2024-06-12 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004748C (en) 2015-11-18 2021-11-16 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN109476745B (zh) * 2016-05-13 2023-11-24 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
EA201990293A1 (ru) * 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018078620A1 (en) 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities
WO2018085533A2 (en) * 2016-11-02 2018-05-11 Apexigen, Inc. Anti-cd40 antibodies in combination and methods of use
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
ES2902670T3 (es) * 2017-01-13 2022-03-29 Taizhou Hanzhong Biopharmaceutics Inc Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
US12053505B2 (en) 2017-08-31 2024-08-06 Multimmune Gmbh Hsp70 based combination therapy
CA3093820A1 (en) * 2018-03-13 2019-09-19 Hibercell, Inc. Beta glucan and cd40 agonist combination immunotherapy
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MX2021001841A (es) * 2018-08-20 2021-05-13 Pfizer Anticuerpos anti-gdf15, composiciones y metodos de uso.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12509521B2 (en) 2018-11-15 2025-12-30 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
ES3016535T3 (en) * 2018-11-23 2025-05-09 Strike Pharma Ab Bi-specific conjugates
TW202039558A (zh) * 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP3976651A1 (en) * 2019-05-28 2022-04-06 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4083210A1 (en) * 2019-12-27 2022-11-02 Interoligo Corporation Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240400706A1 (en) * 2021-10-15 2024-12-05 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
JP2024539940A (ja) * 2021-10-26 2024-10-31 ナビキュア バイオファーマシューティカルズ リミテッド がん及び感染症に対する組み合わせ療法
JP2025521028A (ja) 2022-06-23 2025-07-04 アリゲーター・バイオサイエンス・アーベー 併用療法
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
EP1341909B2 (en) 2000-12-12 2012-04-11 Alligator Bioscience AB A method for in vitro molecular evolution of protein function
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
AU2005323515A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AU2009286247A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a CD40 agonist to a tumor draining lymph node of a subject
CN102695772B (zh) * 2009-09-16 2015-09-16 纳幕尔杜邦公司 装有反式-1,1,1,4,4,4-六氟-2-丁烯的冷却器设备以及在其中制冷的方法
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
SG11201604594SA (en) 2013-12-20 2016-07-28 Hoffmann La Roche Combination therapy with an anti-ang2 antibody and a cd40 agonist
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SG10201912035YA (en) 2015-04-17 2020-02-27 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
US20180142030A1 (en) 2015-06-29 2018-05-24 Bristol-Myers Squibb Company Antibodies to cd40
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.

Similar Documents

Publication Publication Date Title
JP2017524715A5 (Direct)
JP2016537383A5 (Direct)
PH12019502785A1 (en) Anti trbc1 antigen binding domains
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2019510733A5 (Direct)
JP2017500057A5 (Direct)
JP2015532292A5 (Direct)
WO2019086497A3 (en) Combination therapy with targeted ox40 agonists
JP2017048240A5 (Direct)
JP2018516911A5 (Direct)
NZ752294A (en) Cd3 binding antibodies
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
MX2018014950A (es) Terapia de combinacion.
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2014205674A5 (Direct)
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
EP3552665A3 (en) Antibodies
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2020502271A5 (Direct)
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
WO2016090024A4 (en) Combination therapy for treatment of cancer